Dr. Bhattacharjee did her B.Sc in Biotechnology from Bangalore University in 2006 and M.Sc in Applied Genetics from Bangalore University in 2008. She then moved to England to pursue her DPhil (Phd) in Biochemistry from Oxford University where she studied the role of Fml1 and its partner proteins Mhf1 and Mhf2 in promoting genome stability. She was awarded her DPhil in 2012. During her time at Oxford, she was also a tutor at Greene’s College, Oxford. In 2013, Dr. Bhattacharjee moved to Cold Spring Harbor Laboratory, New York. At CSHL, her work has focused on understanding the epigenetic regulation of DNA repair. She is also an academic tutor at the Watson School of Biological studies, the school for graduate studies at CSHL.

Cancer, Genetics and Genomics

Jessica Sember completed her BSN in 2007, at the age of 22 from Mansfield University of Pennsylvania (USA). She is furthering her education with American Sentinel University of Colorado (USA), planning to obtain an MSN with a specialization of Leadership and Organizational Development. Jessica’s nursing career has always been in women’s health, but she has held various roles in labor and delivery, lactation consultant and currently as the perinatal education coordinator, where she facilitates childbirth classes for her health system. Jessica has worked on research projects and has spoken at 2 conferences in the past about breastfeeding.

women’s health, Midwifery

Currently undergoing her PhD on Jewish perspectives to assisted reproductive technologies at University College London alongside professor Joyce Harper and professor Dan Reisel. Alegria completed her BSc in Biomedical Science at Middlesex University at the age of 20 and her MSc in Reproductive Science and Women’s Health at University College London at the age of 21.

Women’s Health

Katie graduated from Manchester Medical School in 2013, and then worked as a foundation doctor in Manchester for 2 years. During this time she completed the DRCOG and FSRH diplomas. She then worked in sexual health for 1 year, completing contraceptive implant and IUD training. She is now completing academic GP training. This research has also been presented at the Faculty of reproductive health conference in 2016 and at the royal college of GP conference in 2016

Reproductive Health

Ms Zhou hui has completed her MD at the age of 26 years from Tongji Medical College, Huazhong University of Science and Technology. She is the director of clinical Laboratory of the Center for Reproductive Medicine, Tongji Medical College, Huazhong University of Science and Technology, China. She has published more than 15 papers in reputed journals.

Reproductive Medicine

Wei-Hong ZHANG, (MD, MPH, PhD, Postdoctoral of University of Oxford). Appointed by the P. R of China, as the State Council Advisor since 2014. She is project leader at International Centre for Reproductive Health (ICRH), Ghent University, Belgium for an EU-funded FP7

Reproductive Medicine

Hilde Masvie Ydstebø completed her MSc in Mother and Child Health at International Perinatal Care Unit, Institute of Child Health, University College London in 2001. She is both a Public Health Nurse and a Psychiatric Nurse. She has been involved in health work both in rural Ethiopia for 11 years and in rural Tanzania for 3 years and is now working with migration health among refugees in Norway.

Child Health, Perinatal Care

Dr Ivan Terziev was born in 1961. He graduated in Medicine in 1987 from the Medical University of Sofia and obtained a specialty in Pathology and Cytology in 1991. Dr Terziev has been working at Tsaritsa Yoanna ISUL University Hospital since 1988, and he is also an Assistant professor of Pathology at the Medical University of Sofia, Bulgaria. Dr Terziev is a member of Bulgarian and European Society of Pathology and Bulgarian-Turkish group on Diseases of Thyroid and Breast. He has numerous publications in Bulgarian scientific journals, as well as more than 20 papers in reputed international ones. Dr Terziev is working in the area of histopathology of head of neck, thyroid gland, gastrointestinal, breast and surgical pathology

Dr Terziev’s research interests include diagnostic and immunohistochemical examination of rare tumors with different localization.

Dr. Kumar received his Ph.D. degree in Neuro-toxicology and is currently a Professor of Biochemistry at The Commonwealth Medical College, Scranton, PA, USA. Dr. Kumar’s research area is focused on the therapeutic targeting of the steroid receptors (SRs) for endocrine-related cancers. Currently, his laboratory is working on a novel therapeutic strategy that could provide cell/tissue-specific target gene regulations in current SHR-based endocrine therapies. In addition to more than 100 publications to his credit, Dr. Kumar has also served as Editorial Board member of more than two-dozen scientific journals, and as expert reviewer on more than two-dozen grant review panels.

Currently, his laboratory is working on a novel therapeutic strategy that could provide cell/tissue-specific target gene regulations in current SHR-based endocrine therapies.

Prof. Kathy Qian Luo received BS, MS from Peking University and Ph.D. from the University of British Columbia in Canada. After finishing Postdoc research at California Institute of Technology in USA, she was working as a Visiting Assistant Professor in the Hong Kong University of Science and Technology and an Associate Professor in Nanyang Technological University of Singapore. Prof. Luo now is a Full Professor in the Faculty of Health Sciences at the University of Macau. She has published 70 journal articles with total citations of 2,000 and h-index of 25. She obtained 7 patents from USA, China, and Singapore.

•Cancer research: Identify driver proteins responsible for cancer cell survival in circulation, metastasis, and drug resistance. •Drug discovery: Discover new anti-cancer agents and elucidate their mechanisms of action. •Metabolic diseases: Study diabetes-related endothelial cell death and discover new biomarkers for diabetes diagnosis. •Aging: Generate transgenic zebrafish for studying apoptosis in neuronal and epithelial cells during aging process.

Dr. Elias is focused on clinical breast cancer research and is the director of the clinical breast oncology program. This comprehensive program includes a weekly multi-disciplinary clinic and tumor board, a hereditary clinic, benign breast complaint clinic, a screening and breast imaging program, in addition to daily breast specialty oncology clinics. The sarcoma program includes consult/new patient clinics as well as followups. Dr. Elias is the principal investigator on numerous national and local therapeutic trials and is institution PI for the SWOG grant. He is a member of the SWOG breast committee. He is also the Associate Director of the Cancer Center for clinical sciences and oversees the Clinical Investigations Core.

breast imaging program, clinical breast cancer research

Dr. Shahla Masood is a Persian-born physician, who currently holds the positions of Professor and Chair of the Department of Pathology at University of Florida College of Medicine – Jacksonville and Chief of Pathology and Laboratory Medicine at Shands Jacksonville. She is also the Director of the Pathology Residency Training Program, as well as Cytopathology and Breast Pathology Fellowship Training Program. In addition, Dr. Masood is the Medical Director of Shands Jacksonville Breast Health Center. An internationally recognized expert in breast cancer diagnosis and prognosis, Dr. Masood has fostered the concept of an integrated multidisciplinary approach in breast cancer care, research, and education.

Breast Cancer Pathology

Amy Levi is currently the Director of the Interdepartmental Nurse-Midwifery Education Program at the University of California San Francisco. This unique program is situated in both the Schools of Medicine and Nursing, and draws from both disciplines to provide graduate education in midwifery and women’s health to registered nurses. She is a founding member of the Center for Women’s Health and Empowerment for the University of California Global Health Institute, and is the liaison to the Global Health Clinical Scholars Program which provides an introduction to global health for students from each of the four health professional schools at UCSF. Dr. Levi is the Clinical Education Consultant for the Health Workforce Pilot Project in the State of California, a study which is evaluating the training trajectory and clinical outcomes of nurse-midwives, nurse practitioners, and physician assistants providing vacuum aspiration abortion care.

Global women’s health, options in reproductive health care, and health care provider education.

2007-present Clinical Associate Professor Department of Obstetrics and Gynecology Stanford University Medical Center Stanford, California 2003-2007 Clinical Assistant Professor Department of Obstetrics and Gynecology Stanford University Medical Center Stanford, California 2000-2003 Assistant Clinical Professor Department of Family and Community Medicine University of California, San Francisco San Francisco, California 1993-1995 Clinical Instructor of Medicine Harbor General Hospital UCLA School of Medicine Division of Endocrinology Torrance, California 1993-1995 Clinical Preceptor Presbyterian Intercommunity Hospital USC Family Practice Residency Program Whittier, California

Endocrinology & Metabolism

Dr. Stachenfeld is an Associate Fellow at the John B. Pierce Laboratory and an Associate Professor of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine. My primary research focus is the impact of reproductive hormones on physiological responses to environmental challenges in women. To this end, my work has emphasized fluid regulatory and cardiovascular responses to exercise and temperature exposure.

Our current studies focus on reproductive hormone effects on blood pressure control, autonomic function and endothelial function.

Mr Ragheed Al-Mufti is Chairman of the West of London Breast Cancer Network. He is also Consultant Breast, Endocrine and Oncological Surgeon at St Mary's Hospital, London, and Honorary Senior Lecturer at Imperial College London School of Medicine (2005 to current). He is a former Consultant in Breast, Endocrine & Oncological Surgery at St Bartholomew's and the Royal London Hospitals (2001 to 2005), and Former Senior Lecturer and Consultant Oncological Surgeon at University College London and Whittington Hospitals (1998 to 2001). Surgical training : Senior Surgical Registrar, Career Surgical Registrar and Surgical Research Registrar, London and North East Thames Region, Bristol & Exeter Surgical SHO Notation. Societies:- Elected Member of the National Executive Committee of BASO (Association of Cancer Surgery) - Member of the Association of Surgeons of Great Britain and Ireland - Member of the Association of Breast Surgeons at BASO - Member of the Thames Cancer Registry Advisory Board - Surgical Tutor of the Royal College of Surgeons of England - Examiner for University of London (Imperial College London and University College London).

Breast and endocrine cancers (surgery)

Parmjit Jat undertook his PhD at the Imperial Cancer Research Fund (now CRUK) and Imperial College London from 1978-1982. This was followed by Postdoctoral research at the MIT Centre for Cancer Research in the laboratory of Dr Philip Sharp. From 1987 to 2003 he was a Group Leader at the UCL Branch of the Ludwig Institute for Cancer Research. Since 2003, he has been a Professor of Molecular Cell Biology at the UCL Institute of Neurology and a member of the MRC Prion Unit.

Breast Cancer biology

The research in my laboratory is focused on understanding signaling networks within cells and how these signaling events modulate gene expression and proliferation. Extracellular signals are routed through signaling networks where they can activate multiple pathways, integrate at different levels, and form positive and negative feedback loops. The laboratory uses a combination of computational modeling and experimental biology to gain a systems understanding of the network and how it regulates gene expression and proliferation.

computational modeling to biochemical analysis of signaling events to proteomics using reverse phase high density lysate microarrays

Jerzy Gubernator studied Biotechnology at Wroclaw University and then has completed his PhD from the same University, Faculty of Biotechnology. Now He is the Head of Department of Lipids and Liposomes at the Faculty of Biotechnology and the director of Academic Center for Biotechnology of Lipid Aggregates in Wroclaw. His main field of investigation are liposomal drug delivery systems. Hi is also specializing in bi functional active drug loading methods. He has published more than 20 papers concerning liposomes and liposomal technology.

Role of Lipids and Liposomes in Breast cancer

Yutaka Tsutsumi graduated from Keio University School of Medicine, Tokyo in 1976, and completed his PhD in 1982. He is the certified pathologist, the certified cytologist and the infection control doctor. He worked for the Department of Pathology, Tokai University School of Medicine, Isehara, Japan for 21 years, and in 2001 he moved as a professor to the Department of Pathology, Fujita Health University School of Medicine, Toyoake, Japan. Dr. Tsutsumi, an oboe player, has published more than 200 English-written papers in varied journals, and released plural single-authored textbooks and web sites in the field of pathology and infectious diseases

Cancer, Pathology

Hiroshi Kobayashi received his Ph.D. in Biochemistry from University of Tokyo in 1974. After his postdoctoral training at Colorado University Medical Center, he started to study adaptation strategies of microorganisms to acidic environments at Chiba University in 1978. His research is focused on mammalian cell functions under acidic conditions from 1996 at Graduate School of Pharmaceutical Sciences, Chiba University. He retired in March 2012 and is a professor emeritus at Chiba University after his retirement. He works as an associate editor of International Immunopharmacology published by Elsevier B.V. from 2014.

Mammalian Cell

Professor Jagat R Kanwar is the Head and team leader of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), School of Medicine, Faculty of Health, Deakin University, Australia. Professor Kanwar has an international reputation and expertise in investigating fundamental and applied molecular signalling aspects of pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, thereby, leading to the development of treatment strategies from bench to bedside. He has more than 150 research publications in high impact factor and peer reviewed international journals, 27 book chapters and 3 edited books

Our nanomedicine laboratory of immunology and molecular biomedical research (NLIMBR) is discovering the novel and safe targeted nanomedicine based nano-nutraceuticals for cancers, autoimmune disorders and inflammatory diseases.

Federico Cattin has completed his graduation at the age of 25 in the Udine University, and post-graduate studies in the Surgical Department of the same University. He is engaged in the studies about breast cancer and has attended a scholarship in the European Institute of Oncology (IEO) in Milan, held by Prof. Umberto Veronesi. He has published 13 papers in reputed journals. Nowadays he works in the Sterzing General hospital in South Tyrol, in Italy

Breast cancer

Dr. Makoto Emoto is the Professor of International University of Health and Welfare in Japan and the Director of Gynecology in Center for Preventive Medicine, Sanno Hospital, Fukuoka, Japan and the former Professor of Fukuoka University Hospital. He received his Ph.D. Degree in 1992 from Fukuoka University Medical School. He was the Research Associate in Department of Obstetrics & Gynecology and Pathology in Cambridge University and St. Edmonds College 2000-2002 and in Cell Biology in Harvard University Medical School 2002. He has authored more than 40 publications in leading journals, especially in Gynecologic Oncology and Ultrasound. He is the Board Certified Fellow of the Japan Society of Gynecologic Oncology, Japan Society of Clinical Oncology, and the Japan Society of Ultrasonics in Medicine.

Gynecologic Oncology, Cancer Stem Cell, Angiogenesis, Ultrasound Imaging, Ultrasound Therapy, Drug Delivery System

Dr. Shahla Masood is a Persian-born physician, who currently holds the positions of Professor and Chair of the Department of Pathology at University of Florida College of Medicine – Jacksonville and Chief of Pathology and Laboratory Medicine at Shands Jacksonville.She is the founder and Editor-in-Chief of The Breast Journal, the founder and past president of the “International Society of Breast Pathology,” the Director of the “Annual Multidisciplinary Symposium on Breast Disease”, “The Breast Cancer Public Forum”, and is currently the President of “The World Society for Breast Health.” She has been named as one of the Top Doctors in America and one of the 20 Top Professors in Oncology at an international level. Dr. Masood is a patient advocate, a partner in community affairs and an accomplished artist and gourmet chef.

She is the founder and Editor-in-Chief of The Breast Journal, the founder and past president of the “International Society of Breast Pathology,” the Director of the “Annual Multidisciplinary Symposium on Breast Disease”, “The Breast Cancer Public Forum”, and is currently the President of “The World Society for Breast Health.”

Marie Wood, MD is professor of medicine, deputy director of the hematology/Oncology Division and director of the Familial Cancer Program. She is a member of the ASCO Prevention Subcommittee and Vice Chair for the CALGB/AIIiance Prevention Committee. Dr. Wood's research focuses around cancer genetics and breast cancer prevention. She has done studies on the barriers to utilization of cancer genetics by primary care providers and recent work has focused on the definition of an adequate family history for oncology professionals. Dr. Wood has received national and local funding to evaluate the link between breast density and vitamin D in women at risk for breast cancer. She is chair of a national (CALGB/AIIiance) study evaluating this effect. Additional studies focus on risk factors for breast cancer and chemoprevention studies of the effects of statins on breast cancer biomarkers such as breast density, various serum and tissue biomarkers.

She is chair of a national (CALGB/AIIiance) study evaluating this effect. Additional studies focus on risk factors for breast cancer and chemoprevention studies of the effects of statins on breast cancer biomarkers such as breast density, various serum and tissue biomarkers.

Yvone Paterson is Professor of Microbiology in the Perelman School of Medicine at the University of Pennsylvania, USA. As a Professor of Microbiology, Paterson is an active educator and trainer and is the PI of several training grants and programs. Her research is in the field of cancer vaccines where she was the first investigator to use Listeria monocytogenes, as a vector to target tumor-associated antigens to the immune system. She has pioneered the application of this organism in vaccine development for over 20 years. Her laboratory was the first to show that this bacterium could be genetically engineered to target antigens to the MHC class I pathway for antigen processing with the induction of cytotoxic T cells, the first to show that it could provide protective immunity against viral challenge and the first to apply the technology for the immunotherapy of cancer. In partnership with Advaxis Inc., a company she founded in 2002, the Listeria based technology is now in a number of clinical trials. Overall, these trials have shown that Listeria based immunotherapeutics are safe to use in humans and result in significantly prolonged survival and, in some cases, complete and partial remissions.

Yvone Paterson research is in the field of cancer vaccines where she was the first investigator to use Listeria monocytogenes, as a vector to target tumor-associated antigens to the immune system.

Professor Khan is Professorial Fellow at the Department of Medicine, University of Melbourne; and School of Public Health and Preventative Medicine, Monash University. She is the Director of the Rehabilitation Services at the Royal Melbourne Hospital. She completed her specialist training in Rehabilitation Medicine in 2000 and ‘Doctor of Medicine’ in 2009. She is a Representative for the Western Pacific Region WHO, ICF Research Branch; Executive member of the WHO International Disaster Committee and Task Force Lead, Committee for Rehabilitation Disaster Relief, ISPRM. She currently holds 9 international academic research appointments in Europe and US. She has a leadership role in rehabilitative care and research, and has published over 250 scientific papers (including 14 Cochrane reviews, 12 book chapters), and is invited speaker at national and international conferences (over 50 presentations in last 5 years).

he has a leadership role in rehabilitative care and research, and has published over 250 scientific papers (including 14 Cochrane reviews, 12 book chapters), and is invited speaker at national and international conferences.

Aysegul A. Sahin is a Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center. she has done Degree-Granting Education in 1980 at University of Ankara School of Medicine, Ankara, Turkey.

Aysegul A. Sahin is a Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center.

P Raghu Ram is amongst the few in the World to have acquired prestigious FRCS from all four Royal Colleges in British Isles (London, Edinburgh, Glasgow, Ireland) & FACS from American College of Surgeons. Having obtained First Place in MS Postgraduate Examination, he completed Subspecialty training in Breast Surgery at world renowned Centers of excellence in the UK. He is the youngest ever recipient of the International Gold Medal (2013) in the 508 years history of the Royal College of Surgeons of Edinburgh.

He is the youngest ever recipient of the International Gold Medal (2013) in the 508 years history of the Royal College of Surgeons of Edinburgh.

Zeina Nahleh is currently Professor of Internal Medicine and Chief of the Division of Hematology-Oncology at the Texas tech Health Sciences Center in El Paso, TX. She is also Co-Director of the Texas Tech Garbar Breast Care Center and Chairperson of the University Medical Center (UMC) Cancer Committee. DR Nahleh was previously employed as Associate Professor and Co-Leader of the Breast Cancer Multidisciplinary team at the Wayne State University- Barbara Ann Karmanos Cancer Institute, aNational Cancer Institute(NCI) - designated Cancer Center. Dr Nahleh’ s research interests, funded by the National Cancer Institute (NCI), the Cancer Prevention Institute of Texas (CPRIT) and several scientific agencies, focus on innovative treatment of breast cancer and improvingthe quality of life of cancer patients. Dr Nahleh is a principal investigator in the Southwest Oncology Group (SWOG) and a member of the NCI- Neoadjuvant and Metastatic breast committees. She is also a member of the American Society of Clinical Oncology and the American College of Physicians. Dr Nahleh has received numerous awards including the Barbara Ann Karmanos‘sHero of Breast Cancer Award, and the TTUHSC –EP Dean’s Excellence in Research Award. She has authored over 50 articles, books and book chapters in the field of cancer and breast cancer research. She has presented in major national and international cancer meetings and serves on the editorial board of numerous world -renowned medical journals.

Nahleh’s research interests, funded by the National Cancer Institute (NCI), the Cancer Prevention Institute of Texas (CPRIT) and several scientific agencies, focus on innovative treatment of breast cancer and improvingthe quality of life of cancer patients.

Alahari Suresh obtained his Bachelor of Science in Biology and Master of Science in Human Genetics from India in 1983 and 1986 respectively. His Ph.D. in Molecular Biology was awarded by Drexel University, Philadelphia in the year 1994. From 1994 to 1998, Dr. Alahari did a post-doctoral fellowship at the University of North Carolina at Chapel Hill. Since 1998, he has been a faculty member at the University of North Carolina and in 2004 joined the LSUHSC as Associate Professor of the Department of Biochemistry. During his tenure at the University of North Carolina, he discovered a novel protein that he termed, Nischarin. Dr. Alahari has published several papers describing the function of Nischarin. He has served on editorial review boards and study sections. In addition he availed visiting professorships at the University of Pennsylvania, Philadelphia and Rockefeller University, New York. Currently he holds endowed professorship named Fred Brazda Professorship.

He has served on editorial review boards and study sections. In addition he availed visiting professorships at the University of Pennsylvania, Philadelphia and Rockefeller University, New York. Currently he holds endowed professorship named Fred Brazda Professorship.

Dr. Henry Lynch established Creighton's Hereditary Cancer Prevention Clinic in 1984, an interdisciplinary clinic where families can find information and services related to all hereditary cancers. Dr. Lynch had the idea to look at cancer from a genetics perspective (he postulated that cancer could be hereditary) rather than focusing exclusively from an environmental point of view (which at the time was the only acceptable cause for cancer in the medical circles). This idea became the main focus of his research for years to come. Dr. Lynch developed what are today regarded as the cardinal principles of cancer genetics: early age of onset of the disease, specific pattern of multiple primary cancers, and Mendelian patterns of inheritance in hundreds of extended families worldwide.

Dr. Lynch developed what are today regarded as the cardinal principles of cancer genetics: early age of onset of the disease, specific pattern of multiple primary cancers, and Mendelian patterns of inheritance in hundreds of extended families worldwide.

Yan-gao Man holds a medical doctor degree in Western Medicine and Master degree in Cell Biology and Microbiology from China, and a PhD in Cell Biology and Anatomy from USA. He received postdoctoral training in Cancer Biology at the American National Cancer Institute. After receiving his PhD in 1998, he has authored and co-authored over 200 published scientific and 46 non-scientific articles, and received 18 research grants and 3 patent certificates. He served as the Director of Gynecologic and Breast Research Laboratory of Armed Forces Institute of Pathology and American Registry of Pathology from 1995 to 2011. Currently, he serves as the Director of Research Laboratory and International Collaboration at Bon Secours Cancer Institute. He is also the editor-in-chief of a SCI (Journal of Cancer) and four newly launched international medical journals. His main research interest focuses on the mechanism of cancer invasion and metastasis. He is the author of the world most updated theories for cancer invasion and metastasis. His theory of cancer invasion has been regarding as more compatible with existing data than the traditional theory. Among all major theories of cancer metastasis, his theory is the only one that can explain all steps of metastasis.

Yan-gao Man main research interest focuses on the mechanism of cancer invasion and metastasis.

Dr Azim is a Professor of Clinical Oncology and immediate past chairman of the Department of Clinical Oncology, Faculty of Medicine, Cairo University. He is the president of the Cairo Oncology Center, one of the largest private Cancer centers in the Middle East region. Dr Azim chairs the scientific committee of the NCCN Middle East chapter and is a member of numerous societies, including the ASCO, ASH, ESMO, ASTRO and the European Blood and Marrow Transplantation Society. He has been principal investigator for many multicenter clinical trials and has published more than 80 papers and he was the chief editor of 2 educational books ( ASCO – PANARAB Lymphoma Conference (1999) and the MD Anderson Cancer Centre / Cairo University joint meeting (2006). Dr Azim serves as a referee for the Annals of Oncology Journal, THE BREAST, BMC Cancer, Chemotherapy journal , Advances in Cancer Research & Treatment, Journal of the Egyptian National Cancer Institute, and the Chinese Clinical Oncology Journal.

He has been principal investigator for many multicenter clinical trials and has published more than 80 papers and he was the chief editor of 2 educational books ( ASCO – PANARAB Lymphoma Conference (1999) and the MD Anderson Cancer Centre / Cairo University joint meeting (2006).

Robert-Alain Toillon has completed his PhD at the age of 28 years from Lille University and postdoctoral studies from Université Libre de Bruxelles. He is the director of “Neurotrophin signaling and therapy resistance” team in INSERM U908 lab. He was hired as cell biology professor of Lille University in 2013 and published more than 30 papers in reputed journals.

He was hired as cell biology professor of Lille University in 2013 and published more than 30 papers in reputed journals.

Jin Cheng has completed his MD and PhD from Beijing Capital Medical University and Paris University XIII in 1986 and 1994, respectively. Following his postdoctoral training at Fox Chase Cancer Center in Philadelphia, he was recruited by Moffitt Cancer Center as an assistant professor in 1997. Currently, he is professor and interim chair of Deportment of Molecular Oncology at Moffitt Cancer Center. He has published more than 130 papers in highly respected journals and has been serving as an editorial board member of in several journals.

He has published more than 130 papers in highly respected journals and has been serving as an editorial board member of in several journals.

Dr. Kumar received his Ph.D. degree in Neuro-toxicology and is currently a Professor of Biochemistry at The Commonwealth Medical College, Scranton, PA, USA. Dr. Kumar’s research area is focused on the therapeutic targeting of the steroid receptors (SRs) for endocrine-related cancers. Currently, his laboratory is working on a novel therapeutic strategy that could provide cell/tissue-specific target gene regulations in current SHR-based endocrine therapies. In addition to more than 100 publications to his credit, Dr. Kumar has also served as Editorial Board member of more than two-dozen scientific journals, and as expert reviewer on more than two-dozen grant review panels.

Currently, his laboratory is working on a novel therapeutic strategy that could provide cell/tissue-specific target gene regulations in current SHR-based endocrine therapies.

Merdan Fayda is an associate professor at Istanbul University, Institute of Oncology, Dept. Of Radiation Oncology. He has been working in the field of radiation oncology since 1999, when he began his education at Istanbul University‘s Institute of Oncology Dept. of Radiation Oncology. Since then, Dr. Fayda has been involved with the Italian Hospital Dept. of Radiation Oncology, Gulhane Military Medical Academy, Dept. of Radiation Oncology, Kocaeli University Faculty of Medicine, Department of Radiation Oncology, and his current affiliation with Istanbul University Institute of Oncology, Department of Radiation Oncology. Dr. Fayda is a member of the Turkish Society of Radiation Oncology, ASTRO and ESTRO. He has several publications which include his thesis on Patient and treatment related factors affecting locoregional recurrence after post-mastectomy adjuvant radiotherapy’, Axillary versus sentinel-lymph-node dissection for micrometastatic breast cancer and his most recent publication of The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer.

Dr. Fayda is a member of the Turkish Society of Radiation Oncology, ASTRO and ESTRO. He has several publications which include his thesis on Patient and treatment related factors affecting locoregional recurrence after post-mastectomy adjuvant radiotherapy’, Axillary versus sentinel-lymph-node dissection for micrometastatic breast cancer and his most recent publication of The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer

Professor Weightman is an experimental physicist with a track record in developing novel instruments. He was a co-applicant on the proposal to construct the ALICE machine which is an energy recovery linear accelerator, the first of its kind in Europe and the only one in the world equipped with a terahertz beamline designed for studies of cancer. ALICE is now operational and Weightman is leading a collaborative programme involving academic scientists and clinicians in exploiting the potential of ALICE for cancer research.

Weightman is leading a collaborative programme involving academic scientists and clinicians in exploiting the potential of ALICE for cancer research.